Sustainability and Global Impact: The video emphasizes @DyadicInc commitment to #sustainability and the potential for these technological improvements to positively impact global #health, #nutrition, and #food sectors. $DYAI #proteins #StocksToWatch youtu.be/7yVzla7Ht8o?si=9U5M…

I don’t normally share milestones like this, but I wanted to give credit where it’s due. I withdrew some of my crypto profits yesterday, and today I was able to buy a car. It’s an amazing feeling to see the progress. Huge thanks to @ines_ferre for the support along the way.

We are actively seeking partners—biotech companies, pharma innovators, public health organizations, and funding agencies—who are focused on accelerating biomanufacturing and real-world deployment. If your goal is to shorten development timelines, improve production efficiency, and expand global access to biologics, we invite you to connect with us to explore collaboration opportunities. $DYAI @GSK @Merck @merckgroup @CSL @SerumInstIndia @AstraZeneca @pfizer @JNJHealthEquity @BARDA @HHS_ASH @SecKennedy @sanofi @BharatBiotech @FDA @SquawkCNBC @WSJ @nytimes @TIME @BostonGlobe

Elon, not all COVID-19 vaccines are alike. There are #mRNA #vaccines, where genetic instructions are delivered into the body and our own cells temporarily produce the antigen that triggers the immune response. There are also recombinant protein vaccines, where the antigen is manufactured outside the body, purified, and then administered to elicit an immune response. And even among protein vaccines, the antigen matters. There is an important distinction between using the full spike protein and using the much smaller, more focused receptor-binding domain (RBD)—a key target for neutralizing antibodies. But there is another critical issue: speed of updating and manufacturing. Traditional mammalian and insect-cell systems used to produce protein vaccines and monoclonal antibodies can take months to develop, scale, manufacture and release an updated product. Faster protein-production platforms such as Dyadic’s C1 can potentially compress that timeline from months to weeks, allowing antigens and mAbs to be updated sooner as viruses mutate, while also producing substantially more protein at potentially lower cost. That matters during an outbreak. The goal should not simply be to have a vaccine or treatment—it should be to have the right antigen or antibody against the circulating variant, produced quickly enough and economically enough to reach people globally. Faster updates. More doses. Lower cost. Greater access, affordability and sustainability. $DYAI @nypost @nytimesbusiness @nytimes @WSJbusiness @WSJ @SquawkCNBC @CNBCFastMoney @CNBCJulianna @MadMoneyOnCNBC @foxandfriends @LizClaman @business @FoxNews @SecKennedy xitter.cf/elonmusk/status/208697…

Tom, there are technologies available today that can rapidly develop outbreak-specific recombinant protein antigens and monoclonal antibodies—and adapt them as viruses mutate. The Gates Foundation, CEPI, the European Vaccines Hub, Fondazione Biotecnopolo di Siena and others are already supporting and evaluating these approaches. Yet access, affordability and sustainable manufacturing too often become secondary to institutional and political considerations. Happy to discuss. The question worth asking is: why so little engagement from WHO, the UN, Africa CDC and other global-health institutions when technologies exist that could help produce more vaccines and treatments, faster and at lower cost? $DYAI @UNReliefChief @DrTedros @DamienMama @julienmh @WHOAFRO @WHO_Europe @WHO @AfricaCDC @UNOCHA @UNOCHA_fr @UNOCHA_DRC @SecKennedy @wellcometrust @DrCharlieWeller

Tom, there are technologies available today that can rapidly develop outbreak-specific recombinant protein antigens and monoclonal antibodies—and adapt them as viruses mutate. The Gates Foundation, CEPI, the European Vaccines Hub, Fondazione Biotecnopolo di Siena and others are already supporting and evaluating these approaches. Yet access, affordability and sustainable manufacturing too often become secondary to institutional and political considerations. Happy to discuss. The question worth asking is: why so little engagement from WHO, the UN, Africa CDC and other global-health institutions when technologies exist that could help produce more vaccines and treatments, faster and at lower cost? $DYAI xitter.cf/UNReliefChief/status/2…

Dairy is just the beginning. Today’s announcement expands the commercial reach of the $DYAI Dapibus™ precision fermentation platform with another strategic European dairy protein agreement, building on our growing portfolio of commercial collaborations. @DyadicInc goal is to create a repeatable platform capable of producing a broad range of high-value proteins and enzymes—faster, efficiently, and at industrial scale. One platform. Multiple products. Expanding commercial opportunities. Learn more: dyadic.com

Standing just feet away from mountain gorillas in Uganda was humbling. Nature remains our greatest innovator—from the forests that harbor incredible biodiversity to the fungi beneath our feet that may help create faster, more affordable vaccines and biologics. Protecting biodiversity isn’t just conservation—it’s investing in humanity’s future. 🇺🇬🦍🌿 #Uganda #GorillaTrekking #Biodiversity #Biotechnology #Conservation $DYAI

One platform investment. Two engineered production platforms. Four major markets. Dapibus® is designed to drive nearer-term commercial revenue across food, nutrition, life sciences and industrial enzymes. C1 is being advanced for longer-term value in vaccines, monoclonal antibodies and therapeutic proteins. The strategy is deliberate: apply shared expression, secretion and fermentation capabilities across multiple protein markets—creating diversified revenue opportunities while addressing one of biotechnology’s biggest challenges: manufacturing more protein, faster and at lower cost. Two platforms. Every market. Grown, not built. $DYAI #Biomanufacturing #Biotech #Dapibus #C1 #SyntheticBiology #PrecisionFermentation #Vaccines #Antibodie

$DYAI Democratizing Global 🌍 Health Equity ⚽️ #Argentina  O - #Spain  1 #worldcup #fifa @DyadicInc #final #score

$DYAI Democratizing Global 🌍 Health Equity ⚽️ #Argentina O - #Spain O #worldcup #fifa @DyadicInc

Biologics medicine is out of reach for 90% + of the world; $DYAI together with @gatesfoundation @CEPIvaccines @NIH @scrippsresearch @UniofOxford @JohnsHopkins @WitsUniversity and many others scientists and organizations globally we are working to change that! @DyadicInc

Might it be a good idea to rapidly develop a faster, more efficient, lower cost approach to produce monoclonal antibodies ? We are here to help $DYAI #BDBV #ebola

We turn DNA into enzymes and proteins that can be produced efficiently and at scale to help feed, fuel and heal humanity more sustainably and affordably. You find it @DyadicInc—we help manufacture it at commercial scale and cost. $DYAI

C1 is now delivering CHO-comparable glycosylation quality (critical for mAb function, half-life, and safety) at microbial economics and speed. $DYAI #mAbs #monclonal #antibodies dyadic.com/global-collaborat…

C1 Monoclonal Antibody Progress for RSV and Malaria Following Full $3.1 Million Gates Foundation Grant Funding - $DYAI Demonstrated plasmid-to-purified-protein production in approximately 15 days!! dyadic.com/global-collaborat…

🇺🇸 Happy 4th of July, America! May your enduring spirit of freedom, generosity, and innovation continue to inspire peace, prosperity, and better health for people around the world. 🌎❤️🤍💙 #Happy4thOfJuly #IndependenceDay #Freedom #Peace #Health #4thOfJuly #250years

The first response to #Ebola isn’t a vaccine. Once infected, a monoclonal antibody can be life-saving. If #antibodies aren’t available or affordable, they’re 100% ineffective. So why is all the focus on #vaccines ? $DYAI @POTUS @SecKennedy @HHS_ASH biospectrumasia.com/influenc…